| CXCL 12 and CXCR 7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma JM Waldschmidt, A Simon, D Wider, SJ Müller, M Follo, G Ihorst, S Decker, ... British journal of haematology 179 (1), 36-49, 2017 | 86 | 2017 |
| Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years M Engelhardt, G Ihorst, O Landgren, M Pantic, H Reinhardt, ... Haematologica 100 (10), 1340, 2015 | 57 | 2015 |
| Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138‐downregulation and inhibition of migration through actin … J Udi, J Schüler, D Wider, G Ihorst, J Catusse, J Waldschmidt, D Schnerch, ... British journal of haematology 161 (1), 104-116, 2013 | 52 | 2013 |
| Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma J Frede, P Anand, N Sotudeh, RA Pinto, MS Nair, H Stuart, AJ Yee, ... Nature cell biology 23 (11), 1199-1211, 2021 | 33 | 2021 |
| Preclinical models of multiple myeloma: a critical appraisal J Schüler, D Ewerth, J Waldschmidt, R Wäsch, M Engelhardt Expert opinion on biological therapy 13 (sup1), S111-S123, 2013 | 30 | 2013 |
| Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease JM Waldschmidt, P Anand, B Knoechel, JG Lohr Seminars in hematology 55 (1), 33-37, 2018 | 29 | 2018 |
| Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in … JM Waldschmidt, A Keller, G Ihorst, O Grishina, S Müller, D Wider, AV Frey, ... Haematologica 103 (10), e473, 2018 | 26 | 2018 |
| Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma JM Waldschmidt, JA Kloeber, P Anand, J Frede, A Kokkalis, V Dimitrova, ... Clinical Cancer Research 27 (23), 6432-6444, 2021 | 25 | 2021 |
| Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma JM Waldschmidt, AJ Yee, T Vijaykumar, RA Pinto, J Frede, P Anand, ... Leukemia 36 (4), 1078-1087, 2022 | 18 | 2022 |
| Multidisciplinary tumor boards: facts and satisfaction analysis of an indispensable comprehensive cancer center instrument M Engelhardt, R Selder, M Pandurevic, M Möller, G Ihorst, J Waldschmidt, ... Deutsche Medizinische Wochenschrift (1946) 142 (9), e51-e60, 2017 | 17 | 2017 |
| Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma JM Waldschmidt, SJ Fruttiger, D Wider, J Jung, AR Thomsen, ... Journal of cancer research and clinical oncology 148 (5), 1045-1055, 2022 | 13 | 2022 |
| Ten color multiparameter flow cytometry in bone marrow and apheresis products for assessment and outcome prediction in multiple myeloma patients V Riebl, SM Dold, D Wider, M Follo, G Ihorst, JM Waldschmidt, J Jung, ... Frontiers in Oncology 11, 708231, 2021 | 12 | 2021 |
| Tracking myeloma tumor DNA in peripheral blood JM Waldschmidt, T Vijaykumar, B Knoechel, JG Lohr Best Practice & Research Clinical Haematology 33 (1), 101146, 2020 | 10 | 2020 |
| Analysis of survival by tumor response: have we learnt any better? G Ihorst, J Waldschmidt, M Schumacher, R Wäsch, M Engelhardt Annals of hematology 94, 1615-1616, 2015 | 10 | 2015 |
| Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib J Eismann, YJ Heng, JM Waldschmidt, IS Vlachos, KP Gray, UA Matulonis, ... Journal of cancer research and clinical oncology 146, 503-514, 2020 | 9 | 2020 |
| Multidisziplinäre tumorboards: fakten und zufriedenheitsanalyse eines unverzichtbaren instruments von tumorzentren M Engelhardt, R Selder, M Pandurevic, M Möller, G Ihorst, J Waldschmidt, ... DMW-Deutsche Medizinische Wochenschrift 142 (09), e51-e60, 2017 | 9 | 2017 |
| From CLL to Multiple Myeloma-Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration. J Lorenz, J Waldschmidt, D Wider, M Follo, G Ihorst, M Chatterjee, ... British Journal of Haematology 174 (6), 2016 | 8 | 2016 |
| Taste Abnormalities Emerging during Anti-Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab A Fleischer, M Roll, F Panther, G Gelbrich, F Reinhardt, C Riedhammer, ... Blood 142, 2403, 2023 | 7 | 2023 |
| Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers B Frank, G Ihorst, G Herget, H Schäfer, J Neubauer, MA Calba, D Textor, ... Annals of Hematology 102 (3), 603-611, 2023 | 7 | 2023 |
| Regulatory programs of B-cell activation and germinal center reaction allow B-ALL escape from CD19 CAR T-cell therapy NG Im, A Guillaumet-Adkins, M Wal, AJ Rogers, J Frede, CC Havig, ... Cancer immunology research 10 (9), 1055-1068, 2022 | 7 | 2022 |
